Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Change in Cash (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Change in Cash for 16 consecutive years, with -$509000.0 as the latest value for Q4 2025.

  • Quarterly Change in Cash rose 90.23% to -$509000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $322000.0 through Dec 2025, up 102.05% year-over-year, with the annual reading at $322000.0 for FY2025, 102.05% up from the prior year.
  • Change in Cash for Q4 2025 was -$509000.0 at Anika Therapeutics, down from $4.8 million in the prior quarter.
  • The five-year high for Change in Cash was $5.6 million in Q3 2023, with the low at -$14.7 million in Q2 2023.
  • Average Change in Cash over 5 years is -$1.9 million, with a median of -$1.3 million recorded in 2021.
  • The sharpest move saw Change in Cash tumbled 1474.51% in 2023, then soared 1162.33% in 2025.
  • Over 5 years, Change in Cash stood at $3.4 million in 2021, then plummeted by 142.52% to -$1.4 million in 2022, then surged by 252.83% to $2.2 million in 2023, then crashed by 335.06% to -$5.2 million in 2024, then soared by 90.23% to -$509000.0 in 2025.
  • According to Business Quant data, Change in Cash over the past three periods came in at -$509000.0, $4.8 million, and -$204000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.